• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    PHYTOCHEMICALS
    June 1, 2022
    1. Stem cell therapy in perspective
    2. Adult Stem cell therapy in perspective
    3. Stem cell therapy for human neurodegenerative disorders–how to make it work
    4. Stable benefit of embryonic Stem cell therapy in myocardial infarction
    5. Stem–cell therapy for diabetes mellitus
    6. New prospects for human Stem–cell therapy in the nervous syStem
    7. Neural Stem cell therapy for neurological diseases: dreams and reality
    8. Stem cell therapy in a caprine model of osteoarthritis
    9. Stem cell therapy and gene transfer for regeneration
    10. Adult Stem cell therapy for the heart
    11. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
    12. Nonmyeloablative Stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of …
    13. Mesenchymal Stem cell therapy in joint disease
    14. The effect of neural embryonic Stem cell therapy in a rat model of cavernosal nerve injury
    15. Stem–cell therapy for amyotrophic lateral sclerosis
    16. Potential of hematopoietic Stem cell therapy in hepatology: a critical review
    17. Becoming immortal: Combining cloning and Stem–cell therapy
    18. 28. Embryonic and adult Stem cell therapy
    19. Dentin regeneration by dental pulp Stem cell therapy with recombinant human bone morphogenetic protein 2
    20. Stem cell and precursor cell therapy
    21. Stem cell therapy for ischemic heart disease
    22. Intervertebral disc cell therapy for regeneration: mesenchymal Stem cell implantation in rat intervertebral discs
    23. Stem cell therapy for ocular disorders
    24. Potential Stem cell therapy and application in neurotrauma
    25. Stem cell therapy of the liver—fusion or fiction?
    26. Stem cell therapy for diabetes: do we need to make beta cells?
    27. Stem cell therapy for myocardial repair: is it arrhythmogenic?
    28. Neural Stem cell therapy in the aging brain: pitfalls and possibilities
    29. Stem cell therapy for urinary incontinence
    30. Stem–cell therapy for renal diseases
    31. Stem cell therapy forcerebral palsy
    32. Genetically engineered Stem cell therapy for tissue regeneration
    33. Emerging neuroprotective strategies for Alzheimer’s disease: dietary restriction, telomerase activation, and Stem cell therapy
    34. Hematopoietic Stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis
    35. In utero Stem cell therapy.
    36. Stem cell therapy for Parkinson’s disease: where do we stand?
    37. Stem cell therapy for the infarcted heart (“cellular cardiomyoplasty”)
    38. Monitoring Stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents
    39. Stem cell therapy for muscular dystrophy
    40. Stem cell therapy in ischemic heart disease
    41. Adult Stem cell therapy for heart failure
    42. Stem–cell therapy for myocardial diseases
    43. Stem cell therapy for the heart
    44. Stem cell therapy of cardiac disease: an update
    45. Applications of magnetic resonance imaging for cardiac Stem cell therapy
    46. The origin and development of the immune syStem with a view to Stem cell therapy
    47. Stem cell origin of cancer and differentiation therapy
    48. Novel approaches to allogeneic Stem cell therapy
    49. Autologous bone marrow-derived Stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases.
    50. Immune ablation and Stem–cell therapy in autoimmune disease-Clinical experience
    51. Stem–cell therapy for amyotrophic lateral sclerosis
    52. Stem cell therapy for neurodegenerative diseases: the issue of transdifferentiation
    53. Hematopoietic Stem cell therapy of autoimmune diseases.
    54. Three-dimensional approach to Stem cell therapy
    55. Editorial Stem cell therapy in human ALS
    56. Stem cell therapy in utero
    57. Human embryonic Stem cell therapy
    58. Stem cell plasticity: the growing potential of cellular therapy
    59. Pancreatic islet and Stem cell transplantation: new strategies in cell therapy of diabetes mellitus.
    60. Cardiovascular disease: potential impact of Stem cell therapy
    61. From Stem cells to beta cells: new strategies in cell therapy of diabetes mellitus
    62. Additional Stem cell therapy for graft failure after allogeneic bone marrow transplantation
    63. Stem cell therapy for ALS: Hope and Reality A discussion paper from the Executive of the European ALS Consortium
    64. Allogeneic cell therapy for patients who relapse after autologous Stem cell transplantation
    65. Stem cell plasticity or fusion: two approaches to targeted cell therapy
    66. Augmentation of virus-specific immunity after hematopoietic Stem cell transplantation by adoptive T-cell therapy
    67. Stem cell therapy for myocardial infarction
    68. Stem cell therapy in acute myocardial infarction
    69. Stem cell therapy for neurological disease and injury.
    70. Correction of ADA-SCID by Stem cell gene therapy combined with nonmyeloablative conditioning
    71. Stem cell therapy for urinary incontinence and pelvic floor disorders: a novel approach
    72. Bone-marrow Stem cells as a source for cell therapy
    73. Stem–cell therapy: what dose should we use?
    74. Stem‐cell plasticity and therapy for injuries of the peripheral nervous syStem
    75. Public Stem cell banks: considerations of justice in Stem cell research and therapy
    76. Hematopoietic Stem cell compartment: acute and late effects of radiation therapy and chemotherapy
    77. Immune ablation and Stem–cell therapy in autoimmune disease: experimental basis for autologous Stem–cell transplantation
    78. Stem cells for cell therapy in Parkinson’s disease
    79. Dendritic-cell therapy after non-myeloablative Stem–cell transplantation for renal-cell carcinoma
    80. Nuclear transplantation, embryonic Stem cells and the potential for cell therapy
    81. Mylotarg™(gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received Stem cell transplantation
    82. cell therapy: Stem cell transplantation, gene therapy, and cellular immunotherapy
    83. Comparison of high-dose therapy and autologous Stem–cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study
    84. Autologous Stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy
    85. Current status and perspectives of Stem cell therapy for the treatment of diabetes mellitus
    86. Neural Stem cells in the developing central nervous syStem: implications for cell therapy through transplantation
    87. Nuclear transplantation, embryonic Stem cells, and the potential for cell therapy
    88. Exogenously regulated Stem cell-mediated gene therapy for bone regeneration
    89. The potential for Stem cell therapy in cystic fibrosis.
    90. High-dose therapy with autologous Stem cell transplantation in patients with peripheral T cell lymphomas
    91. Neuroreplacement therapy and Stem cell biology under disease conditions
    92. Stem cell gene therapy for chronic renal failure
    93. In utero hematopoietic Stem cell therapy
    94. Embryonic Stem cell therapy in experimental stroke: host-dependent malignant transformation
    95. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic Stem–cell transplantation with virus-specific T-cell lines
    96. Prostate Stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
    97. Influenza infections after hematopoietic Stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy
    98. Music therapy for mood disturbance during hospitalization for autologous Stem cell transplantation: a randomized controlled trial
    99. The potential of marrow stromal cells in Stem cell therapy
    100. cell therapy using human embryonic Stem cells
    101. Impact on survival of high-dose therapy with autologous Stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population …
    102. High-dose therapy and autologous peripheral blood Stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential …
    103. High‐dose therapy with autologous haemopoietic Stem cell support for Waldenström’s macroglobulinaemia
    104. A new concept of Stem cell disorders and their new therapy
    105. … response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic Stem cell transplantation. Myeloma Subcommittee of the …
    106. Autologous peripheral hematopoietic Stem cell transplantation restores hematopoietic function following marrow ablative therapy
    107. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous Stem cell transplantation for relapsed B cell lymphomas
    108. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic Stem cell transplantation
    109. Paradigms of adult Stem cell therapy for type 1 diabetes in mice
    110. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic Stem–cell transplantation
    111. … ablation and Stem–cell therapy in autoimmune disease Immunological reconstitution after high-dose immunosuppression and haematopoietic Stem–cell …
    112. Rituximab and ICE as second-line therapy before autologous Stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    113. Heal thyself: Potential applicability of Stem cell therapy in the management of heart disease
    114. Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting
    115. The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic Stem cell transplantation
    116. High-dose immunosuppressive therapy and autologous peripheral blood Stem cell transplantation for severe multiple sclerosis
    117. … impact of cytomegalovirus serostatus of donor and recipient before hematopoietic Stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
    118. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic Stem cell transplantation
    119. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic Stem cell transplantation: risk factors, correlation with DNA …
    120. Prognostic factors for survival and response after high‐dose therapy and autologous Stem cell transplantation in syStemic AL amyloidosis: a report on 21 patients
    121. Parainfluenza virus infections after hematopoietic Stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome
    122. High-dose therapy and autologous peripheral blood Stem cell transplantation for patients with lymphoma
    123. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy
    124. 486: Stem cell therapy in Treatment of Urinary Incontinence: First Clinical Results
    125. Mesenchymal Stem–cell therapy in a regulated environment
    126. therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous Stem cell transplantation
    127. Stem cell therapy in scleroderma
    128. High-dose therapy and autologous blood Stem cell transplantation in POEMS syndrome
    129. First-line therapy with thalidomide and dexamethasone in preparation for autologous Stem cell transplantation for multiple myeloma
    130. Intensive therapy with peripheral Stem cell transplantation in 16 patients with mantle cell lymphoma
    131. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic Stem cell transplantation: Presented in …
    132. Infectious complications after allogeneic Stem cell transplantation: epidemiology and interventional therapy strategies
    133. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and Stem–cell rescue: results of the Chicago Pilot II Study
    134. Viral interleukin-10–engineered autologous hematopoietic Stem cell therapy: a novel gene therapy approach to prevent graft rejection
    135. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
    136. Thoracic transplantation and Stem cell therapy
    137. High-dose therapy with Stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience
    138. P75. Feasibility of Stem cell therapy for intervertebral disc degeneration
    139. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic Stem cell transplantation: a phase …
    140. Imatinib mesylate therapy for relapse after allogeneic Stem cell transplantation for chronic myelogenous leukemia
    141. High-dose therapy and autologous Stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    142. Prognostic factors for survival after high-dose therapy and autologous Stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients …
    143. Should immunoglobulin therapy be used in allogeneic Stem–cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial
    144. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood Stem cell support
    145. Relationship between spermatogonial Stem cell survival and testis function after cytotoxic therapy.
    146. High-dose melphalan, etoposide, total-body irradiation, and autologous Stem–cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not …
    147. High-dose therapy and autologous Stem–cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results …
    148. The role of high-dose therapy and autologous hematopoietic Stem cell transplantation for mantle cell lymphoma
    149. Stem cell strategies for neuroreplacement therapy in Alzheimer’s disease
    150. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic Stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
    151. High-dose intravenous melphalan and autologous Stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of …
    152. Blood Stem cell transplantation as therapy for primary syStemic amyloidosis (AL)
    153. … dose therapy and autologous Stem–cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients …
    154. Endocrine complications of high‐dose therapy with Stem cell transplantation
    155. A human umbilical cord Stem cell rescue therapy in a murine model of toxic liver injury
    156. High-dose therapy and autologous haematopoietic Stem–cell transplantation for HIV-1-associated lymphoma
    157. Hematopoietic Stem cell transplantation: a new therapy for autoimmune disease
    158. Implications of long-term survival in acute Stem cell leukemia of childhood treated with composite cyclic therapy
    159. … and autologous peripheral-blood Stem–cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy
    160. Pluripotent Stem cells–model of embryonic development, tool for gene targeting, and basis of cell therapy
    161. Sequential chemotherapy regimens followed by high-dose therapy with Stem cell transplantation in mantle cell lymphoma: an update of a prospective study
    162. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous Stem–cell transplantation in first remission …
    163. Hematopoietic Stem cell gene therapy: selecting only the best
    164. … reconstitution after autologous hematopoietic Stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications
    165. … followed by high-dose therapy with Stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell …
    166. High-dose therapy and autologous Stem–cell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the …
    167. Hormonal replacement therapy after Stem cell transplantation
    168. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic Stem cell transplantation for relapsed follicular non-Hodgkin …
    169. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and Stem cell rescue
    170. Myeloablative therapy with blood Stem cell transplantation is effective in mantle cell lymphoma.
    171. Temporary corneal Stem cell dysfunction after radiation therapy.
    172. Early autologous Stem–cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian …
    173. Therapeutic Effects of Massage therapy and Healing Touch on Caregivers of Patients Undergoing Autologous Hematopoietic Stem cell Transplant.
    174. Progress toward vector design for hematopoietic Stem cell gene therapy
    175. Embryonic and adult Stem cells as a source for cell therapy in Parkinson’s disease
    176. High-dose therapy followed by autologous hematopoietic Stem–cell infusion for patients with multiple myeloma.
    177. … relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and Stem cell rescue at the time of maximal response to conventional salvage therapy …
    178. cell-replacement therapy with Stem cells in neurodegenerative diseases
    179. Retroviral Stem cell gene therapy
    180. Mesenchymal Stem cells: cell biology and potential use in therapy
    181. High-dose therapy followed by autologous peripheral-blood Stem–cell transplantation for patients with Hodgkin’s disease and non-Hodgkin’s lymphoma using …
    182. Human pancreatic Stem cell and diabetes cell therapy
    183. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence …
    184. Current antiviral strategies for controlling cytomegalovirus in hematopoietic Stem cell transplant recipients: prevention and therapy
    185. Risk to the coronary arteries of intracoronary Stem cell infusion and G-CSF cytokine therapy.
    186. High-dose therapy and autologous Stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT
    187. Therapeutic cloning and Stem cell therapy
    188. Stem cells in cardiovascular disease: from cell biology to clinical therapy
    189. … emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with Stem cell …
    190. … photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic Stem cell …
    191. Haematopoietic Stem cell transplantation and gene therapy in the fetus: ready for clinical use?
    192. High-dose therapy plus autologous hematopoietic Stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV …
    193. … -emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic Stem cell transplantation: a single …
    194. Stem cell transplantation therapy: controversy over ethical issues and clinical relevance.
    195. Adult Stem cell technology-prospects for cell based therapy in regenerative medicine
    196. High-dose chemotherapy followed by autologous Stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis
    197. Second malignancy following high-dose therapy and autologous Stem cell transplantation: incidence and risk factor analysis
    198. Epstein-Barr virus (EBV) reactivation in allogeneic Stem–cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
    199. Myeloablative radiochemotherapy followed by autologous peripheral blood Stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of …
    200. High-dose therapy with autologous Stem–cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the …
    201. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow Stem cell transplant recipients
    202. Hematopoietic Stem cell gene therapy: progress toward therapeutic targets
    203. Stem cell biology and gene therapy
    204. High-dose therapy with autologous Stem cell rescue for pediatric sarcomas
    205. … lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic Stem cell transplantation for severe …
    206. Parainfluenza virus type 3 infections in hematopoetic Stem cell transplant recipients: response to ribavirin therapy
    207. 10 Current status of Stem cell therapy and prospects for gene therapy for the disorders of globin synthesis
    208. Hematopoietic Stem cell gene therapy
    209. Stem cell Gene therapy for the β‐Chain Hemoglobinopathies: Problems and Progressa
    210. Hematopoietic Stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy [see comments]
    211. High-dose consolidation therapy with autologous Stem cell rescue in stage IV breast cancer.
    212. High-dose therapy/autologous Stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
    213. Stem cell therapy and research
    214. High-dose immunoablative therapy with hematopoietic Stem cell support in the treatment of severe autoimmune disease: current status and future direction
    215. High-dose chemotherapy (HDC) and autologous hematopoietic Stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma
    216. High-dose consolidation therapy with autologous Stem–cell rescue in stage IV breast cancer: follow-up report.
    217. Toward Epidermal Stem cell-Mediated ex Vivo Gene therapy of Junctional Epidermolysis Bullosa
    218. Mesenchymal Stem cells from the bone marrow stroma: basic biology and potential for cell therapy
    219. High-dose multimodality therapy with autologous Stem–cell support for stage IIIB breast carcinoma.
    220. … load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic Stem cell …
    221. Single agent dexamethasone for pre-Stem cell transplant induction therapy for multiple myeloma
    222. Efficacy of high-dose therapy and autologous hematopoietic Stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older
    223. Arsenic Trioxide (Trisenox®) therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem cell Transplantation
    224. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic Stem cell transplantation: a pilot study
    225. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and Stem cell …
    226. … high-dose cyclophosphamide without Stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease
    227. High dose therapy and autologous Stem cell transplantation for human immunodeficiency virus‐associated non‐Hodgkin lymphoma in the era of highly active …
    228. Autologous peripheral blood Stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    229. Hematopoietic Stem cell gene therapy: a current overview.
    230. Muscle-derived Stem cells: characterization and potential for cell-mediated therapy
    231. Immunotherapy with rituximab following high-dose therapy and autologous Stem–cell transplantation for mantle cell lymphoma
    232. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA‐identical hematopoietic Stem cell …
    233. … with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood Stem cell transplantation in elderly …
    234. therapy with imatinib mesylate (Glivec) preceding allogeneic Stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute …
    235. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood Stem cell support in unresectable osteosarcoma
    236. Benefit of aggressive multimodality therapy with autologous Stem cell support for intra-abdominal desmoplastic small round cell tumor
    237. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic Stem cell transplantation
    238. Stem–cell therapy for myocardial diseases
    239. Cytokine production during myeloablative and reduced intensity therapy before allogeneic Stem cell transplantation
    240. High risk of therapy-related leukemia after BEAM chemotherapy and autologous Stem cell transplantation for previously treated lymphomas is mainly related to primary …
    241. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic Stem cell transplantation
    242. Results of high-dose therapy and autologous bone marrow/Stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma …
    243. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic Stem cell …
    244. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous Stem cell transplantation in Hodgkin’s disease and non-Hodgkin’s …
    245. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic Stem cell transplantation
    246. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous Stem cell transplant
    247. Stem cell gene therapy, position effects and chromatin insulators
    248. Role for high-dose therapy with autologous hematopoietic Stem cell support in Waldenstrom’s macroglobulinemia
    249. The hematopoietic Stem cell therapy for exploration of deep space
    250. … mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic Stem cell transplantation: a prospective …
    251. … determinant (CD) 34+ cell dose on the cost and consequences of peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma patients in front-line therapy
    252. Sequential high-dose therapy and autologous Stem cell transplantation for treatment of mantle cell lymphoma
    253. High-dose therapy and autologous Stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive …
    254. Adult mesenchymal Stem cells: characterization, differentiation, and application in cell and gene therapy
    255. Evaluation of the risk of therapy-related MDS/AML after autologous Stem cell transplantation
    256. Intensification of therapy using hematopoietic Stem‐cell support for high‐risk neuroblastoma
    257. Strategies for hematopoietic Stem cell gene therapy: insights from computer simulation studies
    258. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic Stem cell transplantation
    259. Stem cell defects after cytoreductive therapy in man.
    260. … with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or Stem cell rescue therapy
    261. Myeloma cell contamination of peripheral blood Stem cell grafts in patients with multiple myeloma treated by high-dose therapy.
    262. Embryonic Stem cell grafting: the therapy of the future?
    263. Transabdominal first trimester embryofetoscopy as a potential approach to early in utero Stem cell transplantation and gene therapy
    264. Single center experience of a new intensive induction therapy for Ewing’s family of tumors: feasibility, toxicity, and Stem cell mobilization properties
    265. Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic Stem cell transplantation
    266. High-dose therapy and autologous Stem cell transplantation in relapsing cutaneous lymphoma
    267. Peripheral blood Stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study
    268. … (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stem cell …
    269. Where next with Stem–cell-supported high-dose therapy for breast cancer?
    270. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high‐dose therapy and peripheral blood Stem cell transplantation
    271. Lymphoid development and function in X-linked severe combined immunodeficiency mice after Stem cell gene therapy
    272. Consolidation therapy with autologous Stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three …
    273. Analysis of feasibility of myeloablative therapy and autologous peripheral Stem cell (PBSC) transplantation in the elderly: an interim report
    274. Embryonic Stem cells in vitro-prospects for cell and developmental biology, embryotoxicology and cell therapy
    275. Peripheral blood Stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood …
    276. An update on the role of high-dose therapy with autologous or allogeneic Stem cell transplantation in mantle cell lymphoma
    277. Hematopoietic Stem cell transplantation for cancer therapy
    278. Hematopoietic Stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid …
    279. Hematopoietic Stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection
    280. Superiority of double over single autologous Stem cell transplantation as first-line therapy for multiple myeloma.
    281. … (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic Stem cell …
    282. Twelve years experience with high-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s disease patients in first remission after MOPP/ABVD …
    283. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood Stem cell transplantation
    284. The role of autologous Stem cell reconstitution in intensive therapy for resistant neoplasms
    285. Nonmyeloablative therapy and allogeneic hematopoietic Stem cell transplantation
    286. Decitabine with allogeneic peripheral blood Stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
    287. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous Stem cell transplantation for salvage therapy in B-NHL
    288. The place of high-dose therapy with haemopoietic Stem cell transplantation in relapsed and refractory Hodgkin’s disease
    289. siRNAs, ribozymes and RNA decoys in modeling Stem cell-based gene therapy for HIV/AIDS.
    290. Clinically‐based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic Stem cell …
    291. Embryonic Stem cell research and therapy: the need for a common European legal framework
    292. … high-dose chemotherapy with granulocyte colony-stimulating factor and autologous Stem–cell transplantation support as first-line therapy in high-risk diffuse large-cell …
    293. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood Stem cell transplantation …
    294. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in children: results of a prospective …
    295. Nutritional support of the patient receiving high-dose therapy with hematopoietic Stem cell support
    296. … Stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell …
    297. … boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high‐risk allogeneic hematopoietic Stem cell transplantation. Scedosporiasis and …
    298. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic Stem cell transplantation
    299. … long‐term hematologic recovery despite a marked quantitative defect in the Stem cell compartment of patients with aplastic anemia after immunosuppressive therapy
    300. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic Stem cell transplant …
    301. Potential use of human Stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias
    302. Effectiveness of high‐dose MCNU therapy and hematopoietic Stem cell autografts treatment of childhood acute leukemia/lymphoma with high‐risk features
    303. Interleukin-2 therapy after bone marrow or Stem cell transplantation for hematologic malignancies.
    304. Cytokines: value-added products in hematopoietic Stem cell gene therapy
    305. … of Multiple Myeloma and Breast Cancer cells by TH9402‐mediated Photodynamic therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem cell …
    306. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic Stem cell transplantation
    307. Autologous Stem cell transplantation for AL amyloidosis: a standard therapy?
    308. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in adults
    309. Hematopoietic Stem cell gene therapy: towards clinically significant gene transfer efficiency.
    310. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic Stem cell transplantation in Philadelphia chromosome–positive acute …
    311. Search for a cure for idiopathic pulmonary fibrosis: is Stem cell therapy a light at the end of a long tunnel?
    312. Stem cell Transplantationfor Leukemias Following Myelodysplastic Syndromesor Secondaryto Cytotoxic therapy
    313. Hematopoietic Stem cell–based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and …
    314. Stem cell therapy (Aastrom Biosciences Inc).
    315. High-dose chemotherapy with Stem cell rescue as initial therapy for anaplastic oligodendroglioma
    316. Directed mobilization of endogenous neural progenitor cells: the intersection of Stem cell biology and gene therapy.
    317. High‐dose intravenous methotrexate followed by autologous Stem cell transplantation as a potentially effective therapy for neurolymphomatosis
    318. 6The role of haematopoietic Stem cell-supported myeloablative therapy for the management of multiple myeloma
    319. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood Stem cell transplantation
    320. Early intensive therapy with autologous Stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry
    321. Ultrasound-guided Stem cell sampling from the early ovine fetus for prenatal ex vivo gene therapy
    322. Hematopoietic Stem cell therapy for multiple sclerosis
    323. The remission status before and the PCR status after high-dose therapy with peripheral blood Stem cell support are prognostic factors for relapse-free survival in …
    324. Hematopoietic Stem cell gene replacement therapy
    325. … by non-myeloablative allogeneic Stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation
    326. Peripheral blood Stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow …
    327. Stem cell therapy for intervertebral disc diseases in vitro and in vivo feasibility study
    328. The leukemogenic risk of integrating retroviral vectors in hematopoietic Stem cell gene therapy applications.
    329. Functional organization of the hematopoietic Stem cell compartment: implications for cancer and its therapy.
    330. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood Stem cell rescue
    331. … suppression and autologous hematopoietic Stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy
    332. Micro-injection-mediated hematopoietic Stem cell gene therapy.
    333. Early allogeneic blood Stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid …
    334. Fetal immune suppression as adjunctive therapy for in utero hematopoietic Stem cell transplantation in nonhuman primates
    335. Development of a modified selective amplifier gene for hematopoietic Stem cell gene therapy
    336. Embryonic Stem cells: a promising tool for cell replacement therapy
    337. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic Stem cell transplant in children: results of a prospective randomized trial
    338. Value of autologous Stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS …
    339. Late infectious complications after high-dose therapy and autologous blood Stem cell transplantation
    340. Stem cell gene therapy: a breakthrough combination magnified by therapeutic Stem cell homing
    341. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous Stem cell transplantation
    342. Peripheral blood Stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma
    343. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after Stem cell transplantation: effective monitoring of CMV infection by quantitative …
    344. Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood Stem cell-based gene therapy
    345. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood Stem cell transplantation for lymphoma
    346. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic Stem cell transplantation
    347. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood Stem cell transplant when started soon after engraftment
    348. Bone marrow Stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type …
    349. Front-line high-dose therapy with autologous Stem cell transplantation for high risk Hodgkin’s disease: comparison with combined-modality therapy
    350. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical Stem cell transplantation
    351. Plasticity of skeletal muscle differentiation generating Stem cell-like phenotype: Possible application to cell therapy for muscular diseases
    352. The Hematopoietic Stem cell therapy for Exploration of Space
    353. Selective expansion of transduced cells for hematopoietic Stem cell gene therapy
    354. Progress towards hematopoietic Stem cell gene therapy.
    355. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic Stem cell …
    356. When to harvest peripheral-blood Stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in …
    357. Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for Stem cell‐based gene therapy
    358. Autologous blood Stem cell transplantation as therapy for autoimmune diseases
    359. High‐dose therapy/Stem cell support: Comparison of mice and humans
    360. High‐dose therapy with Stem cell rescue for pediatric solid tumors: Rationale and results
    361. Transfusion therapy in the patient undergoing hematopoietic Stem cell transplantation
    362. Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood Stem cell transplantation
    363. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic Stem cell transplantation
    364. Multivalent anti-CCR5 ribozymes for Stem cell-based HIV type 1 gene therapy
    365. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic Stem cell transplantation: effect of aminoglycoside therapy
    366. High-dose therapy with Stem–cell transplantation in the malignant lymphomas.
    367. … Stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved Stem cell …
    368. Treatment of mantle-cell lymphomas with the VAD+/− chiorambucil regimen with or without subsequent high-dose therapy and peripheral blood Stem–cell …
    369. … Stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized Stem cell grafts …
    370. High-dose therapy and autologous peripheral Stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone …
    371. … of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood Stem cell …
    372. Technology evaluation: Stem–cell therapy, Aastrom Biosciences Inc.
    373. … colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic Stem cell transplantation for lymphoid …
    374. The present role of bone marrow and Stem cell transplantation in the therapy of children with acute leukemia.
    375. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H. 82 with autologous Stem cell support and cyclosporin A
    376. Stem cell transplantation and gene therapy for HIV-related lymphomas
    377. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood Stem cell support in the adjuvant therapy of high-risk breast cancer: a practical …
    378. High-dose therapy and Stem cell transplantation in follicular lymphoma
    379. Allogeneic hematopoietic Stem–cell transplantation: the next generation of therapy for metastatic renal cell cancer
    380. … for cytomegalovirus disease in patients receiving polymerase chain reaction–based preemptive antiviral therapy after allogeneic Stem cell transplantation depends on …
    381. Autologous peripheral blood Stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
    382. Retroviral vector design studies toward hematopoietic Stem cell gene therapy for mucopolysaccharidosis type I
    383. Adult Stem cells and their importance in cell therapy.
    384. A novel sub-population of bone marrow–derived myocardial Stem cells: potential autologous cell therapy in myocardial infarction
    385. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and Stem cell transplant
    386. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic Stem cell transplantation
    387. High dose therapy and autologous Stem cell transplantation in follicular non-Hodgkin’s lymphoma
    388. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood Stem cell transplantation for invasive thymoma
    389. High dose therapy and autologous hematopoietic Stem cell transplantation in poor risk solid tumors of childhood.
    390. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin’s lymphoma
    391. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and Stem cell rescue. A feasibility study
    392. … carboplatin and interleukin-2 (IL-2) activated autologous Stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma–a …
    393. Filgrastim‐induced Stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging
    394. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and Stem cell gene therapy for AIDS
    395. Intensive therapy and autologous Stem cell transplantation for Hodgkin’s disease in first relapse after combination chemotherapy
    396. Stem cell-based gene therapy
    397. Stem–cell depletion and grid therapy
    398. Adult Stem cell therapy: Imagining Futures in cell Biology
    399. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood Stem cell transplantation and interferon-alpha
    400. … of autologous Stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
    401. Consolidation therapy with autologous blood Stem cell transplantation in a patient with primary plasma cell leukaemia
    402. … therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral Stem cell rescue.
    403. Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous Stem cell transplantation in multiple …
    404. … therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous Stem …
    405. Stem cell therapy: medical advance or moral challenge?
    406. Experience with liposomal Amphotericin‐B in 60 patients undergoing high‐dose therapy and bone marrow or peripheral blood Stem cell transplantation
    407. In utero hematopoietic Stem cell transplantation: a caprine model for prenatal therapy in inherited metabolic diseases
    408. … non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stem–cell transplantation: changing the natural history with monoclonal antibody therapy
    409. Future cure of hearing disorders? Gene therapy and Stem cell implantation are possible new therapeutic alternatives
    410. Thiotepa and cyclophosphamide with Stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and …
    411. High‐dose therapy and autologous blood Stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients
    412. Interferon-α therapy following autologous peripheral blood Stem cell transplantation for adult T cell leukemia/lymphoma
    413. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood Stem–cell support as front-line therapy
    414. Hematopoietic Stem cell gene therapy for Niemann–Pick disease and other lysosomal storage diseases
    415. Neural Stem cells are uniquely suited for cell replacement and gene therapy in the CNS
    416. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood Stem cells
    417. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood Stem cell support is an effective adjuvant treatment for high-risk primary breast …
    418. Donor chimerism and Stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: effects of a retroviral-mediated gene transfer …
    419. Stem cell therapy for severe autoimmune diseases
    420. … use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic Stem cell transplantation as consolidation therapy for high-risk …
    421. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic Stem cell transplantation
    422. … survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with Stem cell transplantation: a retrospective …
    423. therapy-related myelodysplastic syndrome after autologous Stem cell transplantation for breast cancer
    424. … significance of the detection of tumour cells in peripheral blood Stem cell collections in stage II and III breast cancer patients treated with high-dose therapy
    425. Male germ line Stem cells: from cell biology to cell therapy?
    426. High dose therapy with autologous Stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence
    427. Cytomegalovirus following Stem cell transplantation: from pharmacologic to immunologic therapy
    428. High-dose therapy followed by Stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin’s lymphoma
    429. High-dose therapy and autologous Stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
    430. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic Stem cell transplantation for patients with chronic myelogenous …
    431. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood Stem cell transplantation
    432. … of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood Stem cell …
    433. High-dose therapy with Stem cell support in solid tumors
    434. cell sources and support programs for Stem cell research and cell-based therapy in the USA
    435. Immune ablation and Stem–cell therapy in autoimmune disease Introduction
    436. Current status in intrauterine fetal Stem cell therapy
    437. … exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic Stem cell …
    438. Allogeneic Stem cell–Derived “Repair Unit” therapy and the Barriers to Clinical Deployment
    439. Autologous Stem cell therapy for syStemic vasculitis
    440. Diabetes therapy boosts Stem–cell campaign
    441. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood Stem cell transplantation when started soon after …
    442. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood Stem cell transplantation as initial therapy for patients with high-risk non …
    443. Stem–cell gene therapy moves toward approval: an NIH advisory committee gives the nod to a new strategy for genetic therapy based on a rare type of blood cell
    444. Dog leukocyte antigen-haploidentical Stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model
    445. The case for and against high-dose therapy with Stem cell rescue for early poor prognosis Hodgkin’s disease in first remission
    446. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous Stem cell …
    447. Neural Stem cells–a versatile tool for cell replacement and gene therapy in the central nervous syStem: Section Editor: Roderick R McInnes e‐mail: mcinnes@ sickkids …
    448. Cidofovir for cytomegalovirus-preemptive therapy in Stem cell transplant recipients
    449. Autologous Stem cell Transplantation as First Line therapy in Peripheral T cell Lymphomas. Update of a Prospective Multicenter Study.
    450. 1432: The Effect of Neural Embryonic Stem cell therapy in a Rat Model of Cavernous Nerve Injury
    451. In vitro T lymphopoiesis: a model syStem for Stem cell gene therapy for AIDS
    452. Immune therapy for EBV infections after hemopoietic Stem–cell transplant
    453. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous Stem cell support
    454. High‐dose therapy with peripheral blood Stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment
    455. … ‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood Stem cell …
    456. Autologous Stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin’s disease in first complete remission after MOPP/ABVD
    457. Autologous blood Stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong …
    458. High-dose therapy with peripheral blood Stem cell transplantation for patients with relapsed or refractory Hodgkin’s disease: long-term outcome and prognostic factors
    459. … antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through Stem cell factor/granulocyte-macrophage …
    460. A human pluripotent Stem cell in the blood of adults: towards a new cellular therapy for tissue repair
    461. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous Stem cell transplantation is a prognostic factor for event-free survival …
    462. … /nonlymphoid antigen+ acute leukemias: immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential Stem cell.
    463. High dose therapy followed by autologous peripheral blood Stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study
    464. Neural Stem cell therapy
    465. Circulating hematopoietic Stem cell populations in human fetuses: implications for fetal gene therapy and alterations with in utero red cell transfusion
    466. … -associated pulmonary alveolar proteinosis as two hereditary diseases of childhood which are potentially curable by Stem cell gene therapy but require different …
    467. … of interferon tolerance after autologous bone marrow or peripheral blood Stem cell transplants for myeloma patients who have responded to induction therapy
    468. … suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous Stem cell …
    469. Tandem high-dose therapy followed by autologous Stem–cell transplantation for refractory or relapsed high grade non-Hodgkin’s lymphoma with poor prognosis …
    470. Efficacy and toxicity of sequential high-dose therapy with peripheral blood Stem cell support in patients with high-risk breast cancer.
    471. Hematopoietic Stem cell gene therapy: progress and prospects
    472. Purging of contaminating breast cancer cells from hematopoietic Stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation
    473. … cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood Stem cell harvests and bone marrow after therapy
    474. Embryonic Stem cell therapy: Progress and Perspectives
    475. High-dose combined alkylating agent therapy with autologous Stem cell support and chest radiotherapy for limited small-cell lung cancer
    476. Allogenic Stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution
    477. Development of gene therapy for hematopoietic Stem cell using viral vectors
    478. Stem cell therapy: prospects and
    479. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous Stem cell transplantation among patients with AL amyloidosis
    480. Blood Stem cell transplantation and gene therapy of cancer
    481. MESENCHYMAL Stem cell therapy IN GROWTH PLATE CARTILAGE INJURY
    482. Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic Stem cell transplantation
    483. Repetitive low-dose radiation therapy for acute Stem–cell leukemia
    484. Modeling human hematopoietic Stem cell gene therapy in nonhuman primates.
    485. The role of high-dose therapy with hematopoietic Stem cell rescue in low-grade non-Hodgkin’s lymphoma
    486. Intensified daunorubicin in induction therapy and autologous peripheral blood Stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute …
    487. Mobilization of peripheral blood Stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in …
    488. High-dose chemotherapy and autologous Stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer …
    489. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous Stem cell support in patients …
    490. Survival after high-dose therapy with autologous Stem cell support
    491. Stem–cell researchers offer possible therapy for diabetes
    492. Hematopoietic Stem cell gene therapy for inherited bone marrow disorders: past accomplishments and continued challenges
    493. ESHAP+/− Rituximab as Salvage therapy for Relapsed Lymphoma Prior to Stem cell Transplant: Single Institution Experience.
    494. Stem cell (CFU-S) inhibitory peptides: Biological properties and application of pEEDCK as hemoprotector in cytostatic tumor therapy
    495. High-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s lymphoma: a single center experience
    496. Outcome after Second Autologous Stem cell Transplantation as Salvage therapy in Patients with Relapsed Multiple Myeloma.
    497. Complications after high dose therapy and autologous Stem cell transplantation. Retrospective study of an unselected patient sample
    498. Feasibility of using autologous transplantation to evaluate hematopoietic Stem cell-based gene therapy strategies in transgenic mouse models of human …
    499. … in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood Stem cell …
    500. Pulmonary infiltrates after cytokine therapy for Stem cell transplantation: massive deposition of eosinophil major basic protein detected by immunohistochemistry
    501. Hematopoietic Stem cell therapy.
    502. THE ETHICS OF Stem cell therapy
    503. High-dose therapy with autologous bone marrow Stem cell support in primary and metastatic human breast cancer
    504. Hematopoietic Stem cell autografts in support of myeloablative therapy for multiple myeloma
    505. The third conference on hematopoietic Stem cell gene therapy: biology and technology
    506. Survival Following Etanercept therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem cell Transplantation.
    507. Excellent disease eradication by myeloablative therapy and Stem–cell transplantation in patients with acute myelogenous leukemia
    508. Phase I/II trials of autologous peripheral blood Stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the …
    509. NOVEL CLINICAL CONCEPTS ON Stem cell therapy: 336
    510. Monoclonal antibody therapy with autologous peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma
    511. Lamivudine therapy for acute hepatitis B infection following peripheral blood Stem cell transplantation
    512. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood Stem cell support?
    513. … high dose therapy and autologous Stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s disease responding to first line therapy
    514. Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance therapy for Multiple Myeloma Following Autologous Stem cell …
    515. Mesenchymal and nonhematopoietic Stem–cell therapy
    516. Neurosurgical Stem cell therapy
    517. A Stem cell therapy for stroke
    518. Embryonic Stem cell lines for regenerative therapy and pharmaceutical research
    519. Effect of prior therapy and bone marrow metastases on progenitor cell content of blood Stem cell harvests in breast cancer patients
    520. … by campath mab t cell depleted Stem cell allograftP14. Stem cell treatment in inflammatory myopathies: proposals for patient selectionP15. Autologous Stem cell …
    521. ALLOGENEIC Stem cell therapy FOR JOINT DISEASE
    522. … Foundations. Note: A. Hultquist is presently at the Department of Stem cell Biology, Strategic Center for Stem cell Research and Gene therapy, Lund University, S …
    523. High-dose chemotherapy and autologous Stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    524. Early infectious complications after high-dose therapy and autologous blood Stem cell transplantation
    525. High dose therapy and autologous hemopoietic Stem